Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX7, Bevacizumab, and Sintilimab in Unresectable BCLC Stage A HCC
NCT05214339Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2022
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05214339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214339.